HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lia D'Ambrosio Selected Research

Extensively Drug-Resistant Tuberculosis

3/2022Drug resistant TB - latest developments in epidemiology, diagnostics and management.
1/2019Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
4/2018New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
1/2018Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
10/2017Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
7/2017Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
5/2017Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
3/2017Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
3/2017Classifying new anti-tuberculosis drugs: rationale and future perspectives.
2/2017Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lia D'Ambrosio Research Topics

Disease

28Extensively Drug-Resistant Tuberculosis
03/2022 - 12/2012
20Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
03/2022 - 12/2012
18Tuberculosis (Tuberculoses)
01/2022 - 10/2012
3Coinfection
03/2015 - 09/2013
2Pulmonary Tuberculosis
01/2019 - 01/2018
1Infections
02/2022
1Fanconi Syndrome (Syndrome, Fanconi)
01/2018
1Respiratory Insufficiency (Respiratory Failure)
10/2017
1Hypothyroidism
05/2017
1Body Weight (Weight, Body)
01/2017
1Pleural Empyema (Pyothorax)
07/2016
1Tuberculoma
07/2016
1Lung Diseases (Lung Disease)
03/2016
1Noncommunicable Diseases
10/2015
1HIV Infections (HIV Infection)
01/2015
1Respiratory Tract Infections (Respiratory Tract Infection)
10/2012

Drug/Important Bio-Agent (IBA)

21Pharmaceutical PreparationsIBA
03/2022 - 10/2012
16bedaquiline (R207910)IBA
03/2022 - 01/2014
13OPC-67683IBA
03/2022 - 09/2014
6Linezolid (Zyvox)FDA Link
03/2022 - 12/2012
6FluoroquinolonesIBA
03/2022 - 10/2012
6Meropenem (Merrem)FDA LinkGeneric
01/2018 - 06/2013
5Rifampin (Rifampicin)FDA LinkGeneric
03/2022 - 07/2013
5Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric
05/2016 - 06/2013
4Isoniazid (Ftivazide)FDA LinkGeneric
03/2022 - 07/2013
3Clofazimine (Lamprene)FDA Link
01/2018 - 11/2016
3ImipenemFDA Link
05/2016 - 01/2016
2Carbapenems (Carbapenem Antibiotics)IBA
01/2018 - 03/2016
2Anti-Bacterial Agents (Antibiotics)IBA
04/2016 - 01/2016
2Ertapenem (Invanz)FDA Link
03/2016 - 01/2016
2VaccinesIBA
10/2015 - 03/2015
1BCG VaccineFDA Link
02/2022
1Biomarkers (Surrogate Marker)IBA
09/2017
1PyrazinamideFDA LinkGeneric
01/2017
1Oxygen (Dioxygen)IBA
09/2016
1GasesIBA
09/2016
1Nucleic AcidsIBA
10/2015
1Volatile Organic CompoundsIBA
10/2015
1pretomanidIBA
05/2015
1Gatifloxacin (Zymar)FDA Link
03/2015
1Moxifloxacin (Avelox)FDA Link
03/2015

Therapy/Procedure

5Duration of Therapy
04/2018 - 07/2013
3Drug Therapy (Chemotherapy)
03/2022 - 07/2016
3Therapeutics
10/2017 - 03/2015
1Continuity of Patient Care
11/2020
1Art Therapy
01/2015
1Injections
07/2013